Table 3.
Hemodynamics at bosentan initiation and after at least 6 months of treatment.
| Numbers | F/M | Age, y | Treatment | mPAP (mmHg) PVRi (U.m2) before treatment | mPAP (mmHg) PVRi (U.m2) after treatment | Conclusion | References |
|---|---|---|---|---|---|---|---|
| 49 | No data | 11.0 (0–18.0) | Bosentan concomitant prostanoid (n = 24) Bosentan (n = 25) |
mPAP: 64 PVR: 19 |
mPAP: 57 PVR: 15 In 25 patients taking bosentan: mPAP decreased by 9 mmHg, and PVR decreased by 6 mmHg |
mPAP, PVR improved | Rosenzweig et al. (40) |
| 20 | 15/5 | 8.0 (1.2–17.0) | Bosentan | mPAP: no data PVR: 21.7 |
mPAP: 61.45 PVR: 21.74 |
No significant change in PVR, mPAP | Maiya et al. (34) |
| 7 | 3/4 | 9.6 (1.0–16.0) | Sildenafil (n = 5) Bosentan (n = 2) |
mPAP: 91.2 PVR: no data |
mPAP: 86.2 PVR: no data |
mPAP improved | Raposo-Sonnenfeld et al. (35) |
| 64 | 26/38 | 4.3 (1.5–8.9) | Bosentan (n = 23) Prostanoids (n = 15) Sildenafil (n = 9) Combination therapy (n = 11) Calcium channel antagonists (n = 6) |
mPAP: 58 PVR: 19.7 |
mPAP: no data PVR: improved by 23% (23 patients taking bosentan) |
PVRi improved | Moledina et al. (36) |
| 42 | 26/16 | 9.7 | Bosentan | mPAP: 48.8 PVR: 16.5 |
mPAP: 48.3 PVR: 14.1 |
No significant change in mPAP, PVRi | Hislop et al. (16) |
F, Female; M, Male.